LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Hematology Analyzer for Oncology to Deliver Results in Five Minutes

By LabMedica International staff writers
Posted on 01 Jun 2022
Print article
Image: POC hematology analyzer will build upon novel deep-UV cell analysis technology (Photo courtesy of Cellia Science)
Image: POC hematology analyzer will build upon novel deep-UV cell analysis technology (Photo courtesy of Cellia Science)

Currently, blood cell differential testing relies on complex workflows involving expensive instruments, multiple reagents, extensive instrument calibration and maintenance, and operation by highly trained personnel. This results in long turn-around times that delay administration of critical treatments, such as chemotherapy, anti-psychotic medications, and blood transfusions. Now, a blood cell analyzer under development for CLIA-waived use at the point of care aims to provide neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia.

The blood cell analyzer being developed by Cellia Science, Inc. (Fayetteville, AR, USA) has the potential to eliminate delays in providing patients with these critical treatments. The blood cell analyzer is based on label-free deep-UV imaging technology exclusively licensed from the Georgia Institute of Technology (Atlanta, GA, USA).

Hematology analysis is a prerequisite for a number of therapies. Cellia’s technology utilizes the inherent absorption of UV light by biomolecules within cells to generate high quality, label-free images. The use of low wavelength light and the direct detection of biomolecules enable better resolution than the traditional method of staining with Giemsa or similar dyes. While the initial device will be targeted towards oncology, this technology may be extended for use in any blood cell analysis application.

“While many point-of-care diagnostics involve trading accuracy or precision for convenience, preliminary studies implementing Cellia’s imaging technique resulted in high-quality images that provided excellent diagnostic power,” said Kelly Mabry, CEO of Cellia Science.

“Because our technology appears to achieve fast, reliable, quantitative, and simple blood cell analysis in a low-cost configuration, it has great potential to simplify and improve clinical hematological analysis,” said Dr. Francisco Robles, whose lab drove the development of a UV microscopy system that could be adapted for point of care use.

Related Links:
Cellia Science, Inc. 
Georgia Institute of Technology 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more